Download Med Oncology Special Rounds - Dr Peter Hall June 20

SPECIAL ROUNDS
Wednesday, June 20
12:00-1:00 pm
Zane Feldman Auditorium
“Health Economics in Cancer Research: Why, how and when to measure the
cost-effectiveness of new interventions in Oncology.”
Dr Peter Hall, MB ChB MRCP, Clinical Lecturer in Medical Oncology and Health
Economics, University of Leeds, UK.
Specialist Registrar in Medical Oncology at St James Institute of Oncology, Leeds, UK since
2006. 2010-2011 National Institute for Health and Clinical Excellence (NICE) Scholarship.
2008-20012 PhD in Health Economics, and Clinical Trials Methodology, Leeds Institute of
Health Sciences, UK.
Research interests: Health Economics and Outcomes Research in Cancer, Bayesian decision
modelling, Endpoint selection in oncology trials, Economic evaluation in pharmaceutical and
biomarker development
Synopsis: Healthcare providers around the world are increasingly requiring evidence for
cost-effectiveness in addition to the traditional licensing requirements of efficacy and
safety. Consideration of economics is essential if we are to optimise population health from
a finite budget. Contemporary clinical trials frequently fall short of providing adequate
evidence for the accurate estimation of cost-effectiveness. The consequence can be the
uncertainty, delay and controversy which frequently accompanies reimbursement decisions.
There is an urgent need to define, standardise and meet evidence requirements for
economic outcomes. This talk describes the evidence requirements for cost-effectiveness
estimations in cancer. Some of the challenges in generating this evidence from clinical trials
are highlighted. Future strategies for progressing research in this area are suggested. Special
challenges associated with pharmaceutical and biomarker development are also discussed.
Relevant papers:
1. Hall PS; McCabe C; Stein RC; Cameron D. Economic Evaluation of Genomic Test-Directed
Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. JNCI. 2012, 104(1); 56-66.
2. Hall PS, McCabe C, Brown JM, Cameron DA. Health economics in drug development: Efficient
research to inform healthcare funding decisions. European Journal of Cancer, Oct 2010,
46(15);2674-2680.
3.
Hall PS, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron DA. Updated cost-effectiveness
analysis of trastuzumab for early breast cancer: A UK perspective considering long-term toxicity
and pattern of recurrence. Pharmacoeconomics. 2011, 29 (5);415-432